Drugs / COVA322
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02243787 | Apr 2014 → Sep 2015 | psoriasis | Covagen | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVA322 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02243787 ↗ |
| Action | Inhibit | “showed a remarkable ability to inhibit TNF and IL-17A in vitro and in vivo.” PMID 26390837 ↗ Sep 2015 |
| Modality | Protein / enzyme biologic | “COVA322, a Bispecific TNF-α / IL-17A Antibody Fusion Protein” NCT02243787 ↗ |
| Route | Intravenous | “constant-rate i.v. infusion” NCT02243787 ↗ |
| Target | TNF | “showed a remarkable ability to inhibit TNF and IL-17A in vitro and in vivo.” PMID 26390837 ↗ Sep 2015 |